APUS

Apimeds Pharmaceuticals US, Inc.

NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001894525 Biotech & Drug Discovery

$3.05 +0.15 (+5.35%)

Oct 27 4:00 PM ET · prev $2.89

Market cap

$4.5M

Nano cap

1 year

−85.0%

from $20.36 · Oct 28

30 days

−52.3%

from $6.39

52-week range

$1.60–38.95

−92% from high · low Sep 16

Avg volume 20D

5.38M

Oct 6 spike 43.84M

Short interest

73.0K

≈4.7% of shares · −8.2%

Days to cover

1.0

at average volume

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 6 reports · 90 days

Balance 0 bearish · 0 bullish · 6 neutral oldest → newest, height = score

Avg score

·High conf. 3/6

Strongest NEUTRAL Apimeds Pharmaceuticals US, Inc. (APUS) announced via its wholly owned subsidiary MindWave Innovations Inc…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 16 Apimeds Pharmaceuticals failed to file its 2025 Form 10-K on time an…
R May 4 APUS filed an 8-K detailing a comprehensive settlement resolving sha…
X Jul 31 Short interest falls 84.8% to 26.8K
X Aug 14 Short interest falls 44.3% to 14.9K
X Aug 31 Short interest jumps 33.3% to 19.9K
X Sep 15 Short interest falls 48.1% to 10.3K
X Sep 30 Short interest jumps 668.8% to 79.5K
E Oct 6 Trading halt: Halt Resumed: APUS — trading resumed after M (Volatility T…

Signal stack

Where each data set points today.

InstitutionsMIXED

Q2 2026: 1 added (0 new), 0 trimmed or exited.
Short sellersSTEADY

Short interest −8.2% to 73.0K shares. 1.0 days to cover, ≈4.7% of shares.
TrendRANGE

19% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
UBS Group AG	DOUBLED	11,818	$10.6K
UBS Group AG	DOUBLED	4,187	$7.5K
BANK OF AMERICA CORP /DE/	ADD	40	$66.00
JPMORGAN CHASE & CO	ADD	8	$14.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 13, 2026 Press

MindWave Innovations, a subsidiary of APUS, announced that its NILA token will be listed on the Pionex exchange…

Impact 3/10

Oct 13, 2026 Contract

NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide

Trading opens Wednesday, Oct. 14, 2026, at 6 a.m. ...

Oct 13, 2026 SEC

Apimeds Pharmaceuticals US, Inc. (APUS) announced via its wholly owned subsidiary MindWave Innovations Inc. that it…

8-K — Impact 4/10

Oct 1, 2026 SEC

Apimeds Pharmaceuticals US, Inc. disclosed the resignation of Interim CFO Erick Frim effective September 29, 2026, and…

8-K — Impact 2/10

Sep 22, 2026 SEC

Apimeds Pharmaceuticals US, Inc. filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, effective…

8-K — Impact 3/10

Jun 30, 2026 Inst.

UBS Group AG — DOUBLED

11,818 shares ($10.6K)

Mar 31, 2026 Inst.

UBS Group AG — DOUBLED

4,187 shares ($7.5K)

Earnings setup

Estimates

Period	EPS est.	Range	30D rev.	Revenue
Current Q	—	—	—	$0.00
Next Q	—	—	—	$0.00
Current FY	—	—	—	$0.00
Next FY	—	—	—	$0.00

Short side

FINRA· Oct 15, 2026

73,009

shares short

-8.2%

vs prior settlement

1.0

days to cover

≈4.7%

of shares outstanding

Trading halts

Oct 6, 2026	Volatility Pause	Resumed
Oct 5, 2026	Volatility Pause	Resumed
Oct 5, 2026	Volatility Pause	Resumed
Sep 25, 2026	Volatility Pause	Resumed
Jul 30, 2026	Volatility Pause	Resumed